The FDA updated the indication of the JAK inhibitor upadacitinib (Rinvoq) in inflammatory bowel disease (IBD) to account for ...

The label update provides an option for patients who have received at least 1 approved systemic therapy if TNF blockers are clinically inadvisable.

The US Food and Drug Administration (FDA) has approved AbbVie’s supplemental new drug application, updating the indication ...

Updated indication allows the use of RINVOQ® (upadacitinib) prior to the use of tumor necrosis factor (TNF) blocking agents in patients for whom ...

AbbVie (ABBV) on Monday said that the U.S. Food and Drug Administration has approved an update to the indication statement ...

Drugmaker AbbVie Inc raised its full-year profit forecast on Friday, bolstered by signs of recovery in demand for its Botox injection on easing COVID-19 restrictions and strong growth for its latest ...

Rheumatoid Arthritis Treatment Market Boosted by Biologic Advances and Rising Disease Awareness Rheumatoid arthritis ...

Erica Andersen and Christopher Sipes, co-chairs of Covington’s patent litigation group, and co-counsel David Frazier, the global vice chair of Latham’s intellectual property litigation practice, ...

AbbVie Inc. (NYSE:ABBV) is among the high growth mega cap stocks you can buy and hold for the next 3 years. Evan Seigerman, an analyst at BMO Capital, increased the price target on AbbVie Inc.

In rheumatoid arthritis, early and sustained remission is linked to improved long-term outcomes, including preserved joint structure, reduced fatigue, and enhanced quality of life. Therapies that act ...

AbbVie has reached settlements with all generic drugmakers to resolve litigation that challenged their plans to introduce generics of its arthritis drug Rinvoq, per an MSN report. The generic drug ...